{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:08:14Z","timestamp":1789744094917,"version":"4.0.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003491","name":"Herlev Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02993-x","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:34:19Z","timestamp":1789742059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune regulation includes an effector arm: therapeutic implications of phase III IDO\/PD-L1 vaccination in melanoma"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-9605","authenticated-orcid":false,"given":"Mads Hald","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2993_CR1","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.annonc.2026.04.010","volume":"37","author":"JC Hassel","year":"2026","unstructured":"Hassel, J. C. et al. IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma. Ann. Oncol. 37, 999\u20131010 (2026).","journal-title":"Ann. Oncol."},{"key":"2993_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67508-8","volume":"17","author":"S Pedersen","year":"2026","unstructured":"Pedersen, S. et al. Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO\/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma. Nat. Commun. 17, 806 (2026).","journal-title":"Nat. Commun."},{"key":"2993_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41392-026-02710-8","volume":"11","author":"MH Andersen","year":"2026","unstructured":"Andersen, M. H. Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond. Signal Transduct. Target Ther. 11, 130 (2026).","journal-title":"Signal Transduct. Target Ther."},{"key":"2993_CR4","doi-asserted-by":"publisher","first-page":"9519","DOI":"10.1200\/JCO.2026.44.16_suppl.9519","volume":"44","author":"JW Smithy","year":"2026","unstructured":"Smithy, J. W. A phase 2 trial of IO102-IO103 and nivolumab-relatlimab in previously untreated, unresectable melanoma. J. Clin. Oncol. 44, 9519 (2026).","journal-title":"J. Clin. Oncol."},{"key":"2993_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41392-026-02626-3","volume":"11","author":"JH Ruders","year":"2026","unstructured":"Ruders, J. H. et al. Rationale for multi-epitope TGFbeta vaccination in pancreatic cancer: evidence from immunologic and clinical correlates. Signal Transduct. Target Ther. 11, 107 (2026).","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02993-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02993-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02993-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:34:20Z","timestamp":1789742060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02993-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2993"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02993-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"24 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"391"}}